Medical Science Liaison, Cell Therapy Autoimmune - Chicago IL

Medical Science Liaison, Cell Therapy Autoimmune (CTAI)

The Medical Science Liaison (MSL) is a member of a field-based team of scientists who function as an extension of the US Medical Affairs organization. MSLs are responsible for developing and enhancing professional relationships with medical thought leaders involved in various phases of product development. MSLs provide medical information through scientific exchange in a fair-balanced manner and provide clinical/scientific support for our Cell Therapy Autoimmune products at Bristol Myers Squibb in coordination with our Medical Affairs Department.

This is a field-based position and requires professionals with established personal and scientific credibility to interact with thought leaders and centers of excellence. The position involves travel of more than 50%. Responsibilities will include:

• Identify, establish and maintain scientific relationships with Key Opinion Leaders (KOLs)
• Act as primary liaison to investigators interested in developing and performing investigator initiated research
• Develop and execute geography-specific Field Medical and KOL Interaction plans based on therapeutic area objectives and KOL needs
• Partner with other BMS MSL teams to achieve CTAI objectives and goals with rheumatologists and hematologists
• Support patient education initiatives, serving as subject matter expert on BMS pipeline and investigational therapies
• Provide clinical presentations and information in response to unsolicited questions (as appropriate) in academic and healthcare provider settings in both group and one-on-one situations
• Collaborate with the Clinical research and development organization to enhance patient enrolment in BMS-sponsored clinical trials by identifying appropriate trial sites and actively interacting with participating investigators
• Provide scientific support at National, Regional and Local medical congresses/meetings
• Capture and provide timely feedback/insights to internal stakeholders regarding the cell therapy and autoimmune treatment landscape for strategy development